U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H19ClN4O5.ClH.H2O
Molecular Weight 509.34
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TIVOZANIB HYDROCHLORIDE

SMILES

Cc1cc(=NC(=Nc2ccc(cc2Cl)Oc3ccnc4cc(c(cc43)OC)OC)O)[nH]o1.Cl.O

InChI

InChIKey=RQXMKRRBJITKRN-UHFFFAOYSA-N
InChI=1S/C22H19ClN4O5.ClH.H2O/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18;;/h4-11H,1-3H3,(H2,25,26,27,28);1H;1H2

HIDE SMILES / InChI

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C22H19ClN4O5
Molecular Weight 454.8638
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.4609
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: https://www.ncbi.nlm.nih.gov/pubmed/23788831

Tivozanib (formerly AV-951, KRN-951) is a potent and selective VEGFR tyrosine kinase inhibitor and inhibits angiogenesis and vascular permeability in tumor tissues. It completed phase III a trial investigation for the treatment of renal cell carcinomas, but has not been still approved. In addition, this drug is in the phase II of clinical trial for the investigation it in patients with glioblastoma and colorectal carcinoma.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions
PubMed

PubMed

TitleDatePubMed
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.
2011 Oct 30
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
2013 Apr 15
Patents

Sample Use Guides

Advanced Renal Cell Carcinoma: 1.5 mg orally once daily. Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
Route of Administration: Oral
KRN951 (TIVOZANIB) potently inhibited VEGF-induced VEGFR-2 phosphorylation in endothelial cells at in vitro subnanomolar IC50 values (IC50 = 0.16 nmol/L). It also inhibited ligand-induced phosphorylation of platelet-derived growth factor receptor-beta (PDGFR-beta) and c-Kit (IC50 = 1.72 and 1.63 nmol/L, respectively). KRN951 blocked VEGF-dependent, but not VEGF-independent, activation of mitogen-activated protein kinases and proliferation of endothelial cells. In addition, it inhibited VEGF-mediated migration of human umbilical vein endothelial cells.
Substance Class Chemical
Created
by admin
on Sat Jun 26 03:55:15 UTC 2021
Edited
by admin
on Sat Jun 26 03:55:15 UTC 2021
Record UNII
8A9H4VK35Z
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TIVOZANIB HYDROCHLORIDE
DASH   USAN   WHO-DD  
USAN  
Official Name English
TIVOZANIB HYDROCHLORIDE [WHO-DD]
Common Name English
UREA, N-(2-CHLORO-4-((6,7-DIMETHOXY-4-QUINOLINYL)OXY)PHENYL)-N'- (5-METHYL-3-ISOXAZOLYL)-, HYDROCHLORIDE, HYDRATE (1:1:1)
Systematic Name English
TIVOZANIB HYDROCHLORIDE MONOHYDRATE [WHO-DD]
Common Name English
TIVOZANIB HYDROCHLORIDE [USAN]
Common Name English
FOTIVDA
Brand Name English
TIVOZANIB HYDROCHLORIDE MONOHYDRATE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C93259
Created by admin on Sat Jun 26 03:55:15 UTC 2021 , Edited by admin on Sat Jun 26 03:55:15 UTC 2021
Code System Code Type Description
CAS
682745-41-1
Created by admin on Sat Jun 26 03:55:15 UTC 2021 , Edited by admin on Sat Jun 26 03:55:15 UTC 2021
PRIMARY
ChEMBL
CHEMBL1289494
Created by admin on Sat Jun 26 03:55:15 UTC 2021 , Edited by admin on Sat Jun 26 03:55:15 UTC 2021
PRIMARY
PUBCHEM
11547978
Created by admin on Sat Jun 26 03:55:15 UTC 2021 , Edited by admin on Sat Jun 26 03:55:15 UTC 2021
PRIMARY
EU-Orphan Drug
EU/3/10/747 (POSITIVE)
Created by admin on Sat Jun 26 03:55:15 UTC 2021 , Edited by admin on Sat Jun 26 03:55:15 UTC 2021
PRIMARY Treatment of renal-cell carcinoma 9/6/2010 Positive
EVMPD
SUB181449
Created by admin on Sat Jun 26 03:55:15 UTC 2021 , Edited by admin on Sat Jun 26 03:55:15 UTC 2021
PRIMARY
NCI_THESAURUS
C152666
Created by admin on Sat Jun 26 03:55:15 UTC 2021 , Edited by admin on Sat Jun 26 03:55:15 UTC 2021
PRIMARY
FDA UNII
8A9H4VK35Z
Created by admin on Sat Jun 26 03:55:15 UTC 2021 , Edited by admin on Sat Jun 26 03:55:15 UTC 2021
PRIMARY
DRUG BANK
DBSALT002078
Created by admin on Sat Jun 26 03:55:15 UTC 2021 , Edited by admin on Sat Jun 26 03:55:15 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY